Oncology

News

A settlement between Eisai and Torrent Pharma will keep a generic version of blockbuster cancer drug Lenvima off the US market until 2030.

News

AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.

News

NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.

Oncology

Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.

News

New data have shown that the balance between the benefits and harms of prostate cancer screening has improved with longer follow-up.

News

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.